NEW YORK (GenomeWeb News) - Cancer diagnostics developer Almac Diagnostics said today it is undertaking a collaborative study with Oxford University that will seek to create a gene signature to predict the recurrence of ductal carcinoma in situ, a type of breast cancer.

 

The study will use the company’s Breast Cancer DSA microarray to help generate a gene expression signature that would be used to identify patients who are likely to experience a recurrence of DCIS.